Primary biliary acids inhibit hepatitis D virus (HDV) entry into human hepatoma cells expressing the sodium-taurocholate cotransporting polypeptide (NTCP)

PLoS ONE

Volumn 10, Issue 2, 2015, Pages

  Pereira, Isabel Veloso Alves ^a,b   Buchmann, Bettina ^a   Sandmann, Lisa ^a   Sprinzl, Kathrin ^c   Schlaphoff, Verena ^a   Döhner, Katinka ^a   Vondran, Florian ^a   Sarrazin, Christoph ^c   Manns, Michael P ^a   De Oliveira, Cláudia Pinto Marques Souza ^b   Sodeik, Beate ^a   Ciesek, Sandra ^a   Von Hahn, Thomas ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BILE ACID; CHENODEOXYCHOLIC ACID; SODIUM BILE ACID COTRANSPORTER; VIRUS ANTIGEN; VIRUS ENVELOPE PROTEIN; VIRUS RNA; COTRANSPORTER; ORGANIC ANION TRANSPORTER; SODIUM; SODIUM-BILE ACID COTRANSPORTER;

ADULT; ARTICLE; CASE REPORT; CELL MEMBRANE; DELTA AGENT HEPATITIS; FEMALE; HEPATITIS DELTA VIRUS; HEPATOMA CELL; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; MALE; NONHUMAN; POLYMERASE CHAIN REACTION; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; QUANTITATIVE ANALYSIS; VIRUS ENTRY; VIRUS INFECTIVITY; VIRUS PARTICLE; VIRUS RELEASE; VIRUS REPLICATION; CHRONIC HEPATITIS B; DRUG EFFECTS; EXTRACELLULAR SPACE; GENE EXPRESSION REGULATION; LIVER CELL CARCINOMA; LIVER TUMOR; METABOLISM; MIDDLE AGED; MIXED INFECTION; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE; VIROLOGY;

HEPATITIS B VIRUS; HEPATITIS DELTA VIRUS;

ADULT; BILE ACIDS AND SALTS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CHENODEOXYCHOLIC ACID; COINFECTION; EXTRACELLULAR SPACE; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HEPATITIS B, CHRONIC; HEPATITIS D, CHRONIC; HEPATITIS DELTA VIRUS; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; ORGANIC ANION TRANSPORTERS, SODIUM-DEPENDENT; SODIUM; SYMPORTERS; VIRUS INTERNALIZATION; VIRUS REPLICATION;

EID: 84922387580     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0117152     Document Type: Article

References (32)

1. Hughes SA, Wedemeyer H, Harrison PM (2011) Hepatitis delta virus. Lancet 378: 73-85. PMID: 21511329
2. Ott JJ, Stevens GA, Groeger J, Wiersma ST (2012) Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine 30: 2212-2219. doi: 10.1016/j.vaccine.2011.12.116 PMID: 22273662
3. Triolo M, Corte CD, Colombo M (2014) Impact of HBV therapy on the incidence of hepatocellular carcinoma. Liver Int 34 Suppl 1: 139-145. doi: 10.1111/liv.12394
4. Wedemeyer H, Yurdaydin C, Dalekos GN, Erhardt A, Cakaloglu Y, et al. (2011) Peginterferon plus adefovir versus either drug alone for hepatitis delta. N Engl J Med 364: 322-331. doi: 10.1056/NEJMoa0912696 PMID: 21268724
5. Heidrich B, Yurdaydin C, Kabacam G, Ratsch BA, Zachou K, et al. (2014) Late HDV RNA relapse after peginterferon alpha-based therapy of chronic hepatitis delta. Hepatology 60: 87-97. doi: 10.1002/hep. 27102 PMID: 24585488
6. Yan H, Zhong G, Xu G, He W, Jing Z, et al. (2012) Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus. elife 1: e00049. doi: 10.7554/eLife.00049 PMID: 23150796
7. Ni Y, Lempp FA, Mehrle S, Nkongolo S, Kaufman C, et al. (2014) Hepatitis B and D viruses exploit sodium taurocholate co-transporting polypeptide for species-specific entry into hepatocytes. Gastroenterology 146: 1070-1083. doi: 10.1053/j.gastro.2013.12.024 PMID: 24361467
8. Yan H, Peng B, Liu Y, Xu G, He W, et al. (2014) Viral entry of hepatitis B and D viruses and bile salts transportation share common molecular determinants on sodium taurocholate cotransporting polypeptide. J Virol 88: 3273-3284. doi: 10.1128/JVI.03478-13 PMID: 24390325
9. Petersen J, Dandri M, Mier W, Lutgehetmann M, Volz T, et al. (2008) Prevention of hepatitis B virus infection in vivo by entry inhibitors derived from the large envelope protein. Nat Biotechnol 26: 335-341. doi: 10.1038/nbt1389 PMID: 18297057
10. Heidrich B, Manns MP, Wedemeyer H (2013) Treatment options for hepatitis delta virus infection. Curr Infect Dis Rep 15: 31-38. doi: 10.1007/s11908-012-0307-z PMID: 23242761
11. Nkongolo S, Ni Y, Lempp FA, Kaufman C, Lindner T, et al. (2014) Cyclosporin A inhibits hepatitis B and hepatitis D virus entry by cyclophilin-independent interference with the NTCP receptor. J Hepatol 60: 723-731. doi: 10.1016/j.jhep.2013.11.022 PMID: 24295872
12. Watashi K, Sluder A, Daito T, Matsunaga S, Ryo A, et al. (2014) Cyclosporin A and its analogs inhibit hepatitis B virus entry into cultured hepatocytes through targeting a membrane transporter, sodium taurocholate cotransporting polypeptide (NTCP). Hepatology 59: 1726-1737. doi: 10.1002/hep.26982 PMID: 24375637
13. Kullak-Ublick GA, Glasa J, Boker C, Oswald M, Grutzner U, et al. (1997) Chlorambucil-taurocholate is transported by bile acid carriers expressed in human hepatocellular carcinomas. Gastroenterology 113: 1295-1305. doi: 10.1053/gast.1997.v113.pm9322525 PMID: 9322525
14. Kuo MY, Chao M, Taylor J (1989) Initiation of replication of the human hepatitis delta virus genome from cloned DNA: role of delta antigen. J Virol 63: 1945-1950. PMID: 2649689
15. Gehring G, Rohrmann K, Atenchong N, Mittler E, Becker S, et al. (2014) The clinically approved drugs amiodarone, dronedarone and verapamil inhibit filovirus cell entry. J Antimicrob Chemother 69: 2123-2131. doi: 10.1093/jac/dku091 PMID: 24710028
16. von Hahn T, Schulze A, Chicano Wust I, Heidrich B, Becker T, et al. (2011) The novel immunosuppressive protein kinase C inhibitor sotrastaurin has no pro-viral effects on the replication cycle of hepatitis B or C virus. PLoS One 6: e24142. doi: 10.1371/journal.pone.0024142 PMID: 21909416
17. Sureau C (2010) The use of hepatocytes to investigate HDV infection: the HDV/HepaRG model. Methods Mol Biol 640: 463-473. doi: 10.1007/978-1-60761-688-7-25 PMID: 20645068
18. Spearman C (1908) The method of "right and wrong cases" ("constant stimuli") without Gauss's formulae. Br J Psychol 2: 227-242.
19. Kärber G (1931) Beitrag zur kollektiven Behandlung pharmakologischer Reihenversuche. Archiv Exp Pathol Pharmakol 162: 480-487. doi: 10.1007/BF01863914
20. Mederacke I, Bremer B, Heidrich B, Kirschner J, Deterding K, et al. (2010) Establishment of a novel quantitative hepatitis D virus (HDV) RNA assay using the Cobas TaqMan platform to study HDV RNA kinetics. J Clin Microbiol 48: 2022-2029. doi: 10.1128/JCM.00084-10 PMID: 20351206
21. Nakabayashi H, Taketa K, Miyano K, Yamane T, Sato J (1982) Growth of human hepatoma cells lines with differentiated functions in chemically defined medium. Cancer Res 42: 3858-3863. PMID: 6286115
22. Boyer JL (2013) Bile formation and secretion. Compr Physiol 3: 1035-1078. doi: 10.1002/cphy. c120027 PMID: 23897680
23. Jansen PLM, Beuers U, Oude Elferink RPJ (2012) Mechanisms of Bile Secretion. In: Boyer JL, Manns MP, Sanyal AJ, editors. Zakim and Boyer's Hepatology 6th ed: Saunders. pp. 47-63.
24. Konig A, Doring B, Mohr C, Geipel A, Geyer J, et al. (2014) Kinetics of the bile acid transporter and hepatitis B virus receptor Na(+)/taurocholate cotransporting polypeptide (NTCP) in hepatocytes. J Hepatol 61: 867-875. doi: 10.1016/j.jhep.2014.05.018 PMID: 24845614
25. Ambros-Rudolph CM, Glatz M, Trauner M, Kerl H, Mullegger RR (2007) The importance of serum bile acid level analysis and treatment with ursodeoxycholic acid in intrahepatic cholestasis of pregnancy: a case series from central Europe. Arch Dermatol 143: 757-762. doi: 10.1001/archderm.143.6.757 PMID: 17576942
26. Schukfeh N, Metzelder ML, Petersen C, Reismann M, Pfister ED, et al. (2012) Normalization of serum bile acids after partial external biliary diversion indicates an excellent long-term outcome in children with progressive familial intrahepatic cholestasis. J Pediatr Surg 47: 501-505. doi: 10.1016/j.jpedsurg. 2011.08.010 PMID: 22424345
27. Neale G, Lewis B, Weaver V, Panveliwalla D (1971) Serum bile acids in liver disease. Gut 12: 145-152. doi: 10.1136/gut.12.2.145 PMID: 5548561
28. Chen W, Liu J, Gluud C (2007) Bile acids for viral hepatitis. Cochrane Database Syst Rev: CD003181.
29. Sulkowski MS, Kang M, Matining R, Wyles D, Johnson VA, et al. (2014) Safety and antiviral activity of the HCV entry inhibitor ITX5061 in treatment-naive HCV-infected adults: a randomized, double-blind, phase 1b study. J Infect Dis 209: 658-667. doi: 10.1093/infdis/jit503 PMID: 24041792
30. Danzinger RG, Hofmann AF, Schoenfield LJ, Thistle JL (1972) Dissolution of cholesterol gallstones by chenodeoxycholic acid. N Engl J Med 286: 1-8. doi: 10.1056/NEJM197201062860101 PMID: 5006919
31. Thistle JL, Hofmann AF (1973) Efficacy and specificity of chenodeoxycholic acid therapy for dissolving gallstones. N Engl J Med 289: 655-659. doi: 10.1056/NEJM197309272891303 PMID: 4580472
32. Tint GS, Salen G, Shefer S (1986) Effect of ursodeoxycholic acid and chenodeoxycholic acid on cholesterol and bile acid metabolism. Gastroenterology 91: 1007-1018. PMID: 3527851